arrow
Return

Oral magnesium and outcomes in US veterans with heart failure

delete2025-12-01
delete1
PRE
AI
Y
Ying Yin
R
Rebecca B. Costello
G
Gregg C. Fonarow
P
Paul A. Heidenreich
C
Charity J. Morgan
C
Charles Faselis
Y
Yan Cheng
A
Andrew R. Zullo
刘青松 (Simin Liu)
P
Phillip H. Lam
R
Rosanoff, Andrea
J
Jose D Vargas
S
Stephen S. Gottlieb
P
Prakash Deedwania
H
H. J. Moore
Y
Yijun Shao
H
Helen Sheriff
W
Wen‐Chih Wu
Q
Qing Zeng‐Treitler
A
Ali Ahmed *
DOI:10.1093/eurheartj/ehaf881delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Background and Aims Magnesium deficiency is associated with poor outcomes in patients with heart failure (HF), but less is known about the impact of oral magnesium therapy. This study aimed to examine the association of oral magnesium with outcomes in patients with HF and whether it depends on baseline serum magnesium. Methods Of 54 696 Veterans with HF (2001-2023) and hypomagnesemia (serum magnesium <1.7 mg/dL), 10 695 were initiated on oral magnesium (median dose, 420 mg/day). A propensity score-matched cohort of 21 098 patients (treated, n = 10 549) balanced on 71 baseline characteristics was assembled while remaining outcome-blinded. This process was repeated to assemble a matched cohort of 11 634 patients (treated, n = 5817) with normomagnesemia (serum magnesium, 1.7-2.3 mg/dL). Hazard ratios (HR) (95% confidence intervals [CIs]) for one-year outcomes associated with oral magnesium were estimated. Results In the hypomagnesemia cohort, HF hospitalization or death occurred in 21.7% of patients not receiving and 20.1% receiving oral magnesium (HR: 0.91; 95% CI: 0.86-0.97). Respective HRs (95% CIs) in subgroups with serum magnesium 1.6 (n = 5929), 1.3-1.5 (n = 11 293) and <1.3 (n = 3876) mg/dL were 0.99 (0.88-1.12), 0.91 (0.84-0.98; interaction P = .20), and 0.81 (0.71-0.93; interaction P = .03). Respective rates in the normomagnesemia cohort were 17.8% and 19.5% (HR: 1.11; 95% CI: 1.02-1.21). Spline regression analysis revealed that HRs were lower at serum magnesium <1.5 mg/dL, higher at >1.8 mg/dL, and not significant at 1.5-1.8 mg/dL. Conclusions Oral magnesium therapy was associated with a lower risk of HF hospitalization or death in patients with HF and hypomagnesemia. Future clinical trials need to confirm these findings. [GRAPHICS]
Keywords:
Oral magnesium therapy
Heart failure
Magnesium deficiency

Journal

European Heart Journal cover
European Heart Journal
IF:
35.6
Papers:
3.0W
Citations:
9.1W

Organization

U
N
national institutes of health (nih) - usa
Scholars:
10.2W
Papers: 8.2W
Citations: 111
U
University of Alabama Birmingham
Scholars:
2.1W
Papers: 1.8W
Citations: 29
U
US Department of Veterans Affairs
Scholars:
3.8W
Papers: 3.3W
Citations: 47
V
veterans health administration (vha)
Scholars:
2.6W
Papers: 2.1W
Citations: 40
G
George Washington University
Scholars:
1.6W
Papers: 1.4W
Citations: 1.7W
University of California System cover
University of California System
Scholars:
37.2W
Papers: 33.6W
Citations: 6.6K
researcher View more organizations